Good morning, everyone, and welcome to another working week. We hope the weekend respite, which was an extended treat for some, was relaxing and invigorating, because that oh-so-familiar routine of meetings, conference calls, deadlines, and the like has predictably returned. You knew this would happen, though, yes? The world keeps spinning no matter how hard we may sometimes try to slow it down. So, to cope, we are brewing a cup of stimulation and invite you to join us. Meanwhile, here are some tidbits to get you started. Hope your day goes well and do keep in touch …

Novartis (NVS), which last week reported positive interim data for its experimental spinal muscular atrophy treatment, disclosed that an investigation is underway into whether a second clinical trial death could be related to the treatment, Reuters writes. The drug maker also reported that in addition to the death, a 6-month-old patient with type 1 SMA had recently died after undergoing treatment with the therapy, called Zolgensma, in a European trial. Food and Drug Administration approval is expected within weeks. The FDA submission was based on findings from a trial of 15 babies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy